Cargando…

Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

Detalles Bibliográficos
Autor principal:	Dhillon, Sohita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443610/ https://www.ncbi.nlm.nih.gov/pubmed/30900188 http://dx.doi.org/10.1007/s40261-019-00780-x

Ejemplares similares

Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Correction to: Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Correction to: Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Correction to: Zavegepant: First Approval
por: Dhillon, Sohita
Publicado: (2023)

Correction to: Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Correction to: Moxetumomab Pasudotox: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Neratinib for breast cancer
Publicado: (2019)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2022)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Correction to: Mastectomy with one-stage or two-stage reconstruction in breast cancer: analysis of early outcomes and patient’s satisfaction
por: Gurrado, Angela, et al.
Publicado: (2022)

Dual targeting multiwalled carbon nanotubes for improved neratinib delivery in breast cancer
por: Abu Lila, Amr Selim, et al.
Publicado: (2023)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy
por: Aleanizy, Fadilah Sfouq, et al.
Publicado: (2020)

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
por: Chan, Arlene, et al.
Publicado: (2022)

Correction: Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer
Publicado: (2014)

Correction: Multi-stage feature selection (MSFS) algorithm for UWB-based early breast cancer size prediction
por: Vijayasarveswari, V., et al.
Publicado: (2021)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Neratinib protects pancreatic beta cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Correction: How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment
Publicado: (2016)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m7g0qlv6densridleu1tf2rukt